Skip to main content

4 Result(s)

within Brian Lord Remove this filter

and

  1. Article

    Open Access

    Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans

    Orexin neurons originating in the perifornical and lateral hypothalamic area project to anxiety- and panic-associated neural circuitry, and are highly reactive to anxiogenic stimuli. Preclinical evidence sugge...

    Giacomo Salvadore, Pascal Bonaventure, Anantha Shekhar… in Translational Psychiatry (2020)

    Download PDF (549 KB) View Article

  2. No Access

    Article

    Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia

    Emerging data continues to point towards a relationship between neuroinflammation and neuropsychiatric disorders. ATP-induced activation of P2X7 results in IL-1β release causing neuroinflammation and microglia...

    Anindya Bhattacharya, Brian Lord, Jan-Sebastian Grigoleit… in Neuropsychopharmacology (2018)

  3. No Access

    Article

    JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats

    A few recent studies suggest that brain histamine levels and signaling via H3 receptors play an important role in modulation of alcohol stimulation and reward in rodents.

    Ruggero Galici, Amir H. Rezvani, Leah Aluisio, Brian Lord… in Psychopharmacology (2011)

  4. No Access

    Article

    In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor

    The lack of potent, selective, brain penetrant Y2 receptor antagonists has hampered in vivo functional studies of this receptor.

    James R. Shoblock, Natalie Welty, Diane Nepomuceno, Brian Lord… in Psychopharmacology (2010)